An engineered bacterium for producing L-homoserine by fermentation, and its construction method and application
By knocking out the ygeA gene of E. coli and building an expression vector, the problem of fermentation and low yield and purity of L-homoserine is solved, and a more efficient and environmentally friendly production process is achieved, which is suitable for industrial applications.
Patent Information
- Application Number
- CN202310958813.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-08-01
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-08-01
AI Technical Summary
The prior art produces limited output and low purity when fermenting L-homoserine, which has problems with environmental pollution and the use of toxic raw materials, making it difficult to meet the needs of industrial applications.
By knocking out the ygeA gene of E. coli and combining expression vectors of thrB, thrA, ppc and asd genes, engineered bacteria were constructed to improve the fermentation yield and purity of L-homoserine.
The fermentation yield and purity of L-homoserine is significantly improved, the demand for using toxic raw materials is reduced, and a more environmentally friendly and economical production process is achieved.
Smart Images

Figure BDA0004370897010000041 
Figure BDA0004370897010000051 
Figure BDA0004370897010000081
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of genetic engineering, and in particular to an engineering bacterium for producing L-homoserine by fermentation, and a construction method and application thereof. Background Art
[0002] L-homoserine (2-amino-4-hydroxybutyric acid) is a precursor of methionine, lysine and threonine, and participates in a variety of physiological and biochemical reactions and multiple biological metabolic processes in the body, and has important physiological functions and application values. L-homoserine is also an important platform compound, which is used as a raw material or intermediate to synthesize a variety of chemical products and is widely used in the fields of food, cosmetics, medicine and feed. At present, most of the commercially available glufosinate ammonium is a mixture of D- and L-types, but only L-glufosinate ammonium has herbicidal activity. L-homoserine can be used to synthesize L-glufosinate ammonium, reduce the amount and cost of herbicides, and reduce harm to soil and crops. Therefore, L-homoserine is used to synthesize a new pesticide, L-glufosinate ammonium, and has broad market prospects.
[0003] At present, the synthesis methods of L-homoserine are mainly chemical method and biological enzyme method. The chemical method uses relatively expensive L-methionine as raw material, and uses methyl iodide or methyl bromide with serious biological toxicity as methylating agent, and generates sulfide, which pollutes the environment. The biological enzyme method uses pyruvic acid and aldehyde compounds as raw materials, and reacts to obtain homoserine under the common catalysis of aldolase, formate dehydrogenase and amino acid dehydrogenase, and also needs to use toxic raw materials (formaldehyde and formic acid) and expensive coenzymes. Microbial fermentation has many advantages such as low cost, mild conditions, less environmental pollution, etc., and is the preferred process for producing various amino acids.
[0004] At present, the metabolic engineering transformation strategies for producing L-homoserine by fermentation mainly include knocking out the degradation or branch metabolic pathway genes thrB, metA, lysA, and enhanced expression of aspartate kinase feedback inhibition mutant genes thrA or lysC, L-aspartate semialdehyde dehydrogenase gene asd, pyruvate carboxylase gene pyc or phosphoenolpyruvate carboxylase gene ppc, etc. However, the improvement of L-homoserine fermentation yield is still limited, and the fermentation purity is low, and the subsequent extraction is difficult. Therefore, it is necessary to develop new engineering bacteria construction strategies to further improve the fermentation yield and purity of L-homoserine. Summary of the invention
[0005] The purpose of the present invention is to provide an engineered bacterium for producing L-homoserine by fermentation, and a construction method and application thereof, so as to solve the problems existing in the above-mentioned prior art. The engineered bacterium can improve the fermentation yield and purity of L-homoserine and has important industrial application value.
[0006] To achieve the above object, the present invention provides the following solutions:
[0007] An engineered bacterium for producing L-homoserine by fermentation, wherein the initial strain of the engineered bacterium is Escherichia coli, and the engineered bacterium is obtained by completely or partially knocking out the ygeA gene of the Escherichia coli;
[0008] The nucleotide sequence of the ygeA gene is shown in SEQ ID NO.5.
[0009] Furthermore, the engineered bacteria also completely or partially knock out the thrB gene;
[0010] The nucleotide sequence of the thrB gene is shown in SEQ ID NO.4.
[0011] Furthermore, the engineered bacteria also include an expression vector for overexpressing the thrA mutant gene;
[0012] The nucleotide sequence of the thrA mutant gene is obtained by mutating the bases at 1297-1299 bp of the nucleotide sequence shown in SEQ ID NO.1 into bases encoding arginine.
[0013] Furthermore, the engineered bacteria also include an expression vector for overexpressing the ppc gene and / or the asd gene;
[0014] The nucleotide sequence of the ppc gene is shown in SEQ ID NO.2;
[0015] The nucleotide sequence of the asd gene is shown in SEQ ID NO.3.
[0016] Furthermore, the Escherichia coli is Escherichia coli K12MG1655.
[0017] The present invention also provides a method for constructing an engineering bacterium for producing L-homoserine by fermentation, comprising the following steps:
[0018] The thrB gene of Escherichia coli was completely or partially knocked out to obtain E. coliMG1655△thrB with loss of thrB gene function;
[0019] The ygeA gene of the E. coli MG1655 △thrB is completely or partially knocked out to obtain E. coli MG1655 △thrBygeA in which the thrB gene and the ygeA gene have lost their functions;
[0020] Introducing an expression vector for overexpressing the thrA mutant gene, the ppc gene and the asd gene into the E. coli MG1655ΔthrBygeA to obtain the engineered bacteria;
[0021] The nucleotide sequence of the thrA mutant gene is obtained by mutating the bases at 1297-1299 bp of the nucleotide sequence shown in SEQ ID NO.1 to bases encoding arginine;
[0022] The nucleotide sequence of the ppc gene is shown in SEQ ID NO.2;
[0023] The nucleotide sequence of the asd gene is shown in SEQ ID NO.3;
[0024] The nucleotide sequence of the thrB gene is shown in SEQ ID NO.4;
[0025] The nucleotide sequence of the ygeA gene is shown in SEQ ID NO.5.
[0026] Furthermore, the thrB gene and the ygeA gene are completely or partially knocked out using the CRISPR / Cas9 method.
[0027] Furthermore, the Escherichia coli is Escherichia coli K12MG1655.
[0028] The present invention also provides the use of the above-mentioned engineering bacteria in the fermentation production of L-homoserine.
[0029] The present invention also provides a method for producing L-homoserine by fermentation, comprising the step of producing L-homoserine by fermentation using the above-mentioned engineered bacteria.
[0030] The present invention discloses the following technical effects:
[0031] The ygeA gene encodes an amino acid racemase that catalyzes L-homoserine to produce D-homoserine, and the enzyme has high affinity and catalytic activity for L-homoserine. The present invention constructs an engineered bacterium for producing L-homoserine by fermentation by knocking out the ygeA gene. The engineered bacterium can improve the yield and purity of L-homoserine produced by fermentation of Escherichia coli, and has important industrial application value. DETAILED DESCRIPTION
[0032] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0033] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0034] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0035] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0036] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0037] Unless otherwise specified in the following examples, the technical means used in the examples are conventional means well known to those skilled in the art and commonly used instruments and reagents on the market. References may be made to Molecular Cloning Experiment Guide (3rd Edition) (Science Press), Microbiology Experiment (4th Edition) (Higher Education Press) and the manufacturer's instructions of corresponding instruments and reagents.
[0038] The strains and vectors used in the present invention can be purchased from commercial and publicly available strains and plasmid collections, including Escherichia coli K12MG1655: ATCC number 700926; pACYC184 plasmid: NEB, product catalog number E4152S; plasmid pcas9 purchased from Addgene, item number 62225; plasmid pTargetF purchased from Addgene, item number 62226.
[0039] Example 1 Construction of expression vector pACYC184-thrA-ppc-asd
[0040] Using the E. coli MG1655 genome as a template, upstream fragment primers H1 and H2, and downstream fragment primers H3 and H4 were used, and the upstream and downstream fragments of thrA (the thrA gene sequence is shown in SEQ ID NO.1) were amplified using Norwegian PhantaFlash high-fidelity DNA polymerase. The upstream and downstream fragments of thrA were recovered by gel excision and these two fragments were used as templates. The two end primers H1 and H4 were used by overlapping PCR (overlap PCR) to obtain the gene thrA introduced with mutations by overlapping primers H2 and primers H3. G433R The promoter PJ23105 was introduced by primer H1.
[0041] After the PCR reaction is completed, the PCR product is detected by gel electrophoresis, and the band of the correct size is recovered by gel cutting and purified for later use.
[0042] The pACYC184 plasmid and the amplified thrA fragment were double-digested with XbaI and HindIII restriction endonucleases, and the gene fragments after digestion were recovered using a gel recovery kit. The digested pACYC184 plasmid and the thrA fragment P were ligated with T4 ligase. PL , transformed into DH5α competent cells, screened positive transformants after subculture, extracted plasmids and sequenced for verification, and the plasmid pACYC184-thrA with the correct sequence was further connected to the ppc gene.
[0043] H1:GC TCTAGA TTTACggctagctcagtcctaggtactatgctagcTTTTCGACCAAAGGTAACGAG (SEQ ID NO.7), the underlined sequence is the XbaI restriction enzyme recognition site, and the sequence in italics is the promoter PJ23105 sequence; H2: CGTTCAGAAGATCTCTGAGCAATGGCGACA (SEQ ID NO.8);
[0044] H3:TGTCGCCATTGCTCAGAGATCTTCTGAACG (SEQ ID NO.9);
[0045] H4:CCC AAGCTT AGACTCCTAACTTCCATGAGA (SEQ ID NO. 10), the underlined sequence is the HindIII restriction enzyme recognition site;
[0046] H5:CCC AAGCTT ACATTTCCATAAGTTACGCTT (SEQ ID NO. 11), the underlined sequence is the HindIII restriction enzyme recognition site;
[0047] H6:AA GATATC GTGTTAGAACAGAAGTATTTCAG (SEQ ID NO. 12), the underlined sequence is the EcoRV restriction enzyme recognition site;
[0048] H7:GC TCTAGA GACTTTCTGCGTGCTAACA (SEQ ID NO. 13), the underlined sequence is the XbaI restriction enzyme recognition site;
[0049] H8:GC TCTAGA TCCTGTATTACGCACTAACA (SEQ ID NO. 14), the underlined sequence is the XbaI restriction enzyme recognition site.
[0050] PhantaFlash ultra-fidelity DNA polymerase PCR reaction system is shown in Table 1:
[0051] Table 1
[0052] Element volume 2× DNA polymerase buffer 25μL Forward primer (10 μmol / L) 2μL Reverse primer (10 μmol / L) 2μL DNA template 0.5μL Sterile deionized water Make up to 50 μL
[0053] The PCR reaction conditions are shown in Table 2:
[0054] Table 2
[0055]
[0056]
[0057] Using E. coli MG1655 genome as template, primers H5 and H6, and Novozyme PhantaFlash high-fidelity DNA polymerase, ppc gene (sequence shown in SEQ ID NO. 2) was amplified. After the PCR reaction, the PCR product was detected by gel electrophoresis, and the band of the correct size was recovered by gel cutting and purified for later use.
[0058] The pACYC184-thrA plasmid and the ppc fragment were double-digested with HindIII and EcoRV restriction endonucleases, respectively, and the digested fragments were recovered again using a gel recovery kit; the double-digested pACYC184-thrA plasmid fragment and the ppc gene fragment were connected with T4 ligase, transformed into DH5α competent cells, and positive transformants were screened after subculture. The plasmid was extracted and sequenced to obtain the correct recombinant vector pACYC184-thrA-ppc, which was further connected to the asd gene.
[0059] Using E. coli MG1655 genome as template, primers H7 and H8, and Novozyme PhantaFlash high-fidelity DNA polymerase, amplified the asd gene (sequence shown in SEQ ID NO.3). After the PCR reaction, the PCR product was detected by gel electrophoresis, and the band of the correct size was recovered by gel cutting and purified for later use.
[0060] The pACYC184-thrA-ppc plasmid and the amplified asd gene were digested separately using XbaI restriction endonuclease, and the digested fragments were recovered using a gel recovery kit again; the digested pACYC184-thrA-ppc was treated with alkaline phosphatase, and then the double-digested asd gene fragments were ligated with T4 ligase and transformed into DH5α competent cells. After subculture, positive transformants were screened, and the plasmid was extracted for sequencing verification to obtain the correct recombinant vector pACYC184-thrA-ppc-asd.
[0061] Example 2 Knockout of thrB gene
[0062] The gene mutation kit from NEB ( Site-Directed Mutagenesis Kit, catalog number E0552S), primers H9 and H10 were designed to mutate the pTargetF vector according to the kit instructions. The mutated N20 sequence was TGGTTCTGACGGCAGCTTAT (SEQ ID NO.27), targeting the thrB gene (sequence shown in SEQ ID NO.4). The mutated pTargetF was named pTargetFtB.
[0063] Using the E. coli MG1655 genome as a template, primers H11 and H12 were used to amplify the upstream sequence of the thrB gene using Novozymes PhantaFlash high-fidelity DNA polymerase, and primers H13 and P14 were used to amplify the downstream sequence of the thrB gene. The upstream and downstream fragments were recovered by gel excision and these two fragments were used as templates. The gene editing template DonortB for knocking out thrB was obtained by overlapping PCR using primers H11 and H14 at both ends.
[0064] The pCas9 plasmid was transformed into MG1655 coated with 50 mg / L kanamycin resistance plates and cultured at 30°C to obtain strain MG655 / pCas9. The MG1655 / pCas9 bacterial lawn was picked up and placed in a 500 mL shake flask containing 50 mL of LB containing kanamycin and cultured at 30°C and 220 rpm. When the culture medium OD 600 When the OD was 0.2, arabinose with a final concentration of 10 mM was added for induction. 600Prepare competent cells when the p-value is 0.4. Take 2 microliters of pTargetFtB plasmid and 10 microliters of DonortB template DNA, electrotransform into MG655 / pCas9 competent cells, spread on double-resistant plates containing 50 mg / L kanamycin and 50 mg / L spectinomycin, and culture at 30°C. Use primers H11 and H14 to identify single colonies with bases 91-795 of the thrB gene knocked out. Select the single colony with the correct sequencing, add 0.2mM IPTG to culture, eliminate the pTargetFtB plasmid, and obtain the engineered bacteria E.coliMG1655△thrB / pCas. Further inoculate with non-resistant LB liquid culture medium, culture at 37°C for 12 hours, dilute and spread on LB plates, and obtain the engineered bacteria E.coliMG1655△thrB that eliminates the pCas plasmid.
[0065] H9:GCAGCTTATGTTTTAGAGCTAGAAATAGC (SEQ ID NO. 15);
[0066] H10:CGTCAGAACCAGACTAGTATTATACCTAGG(SEQ ID NO.16);
[0067] H11:GGCAATGACGTTACAGCT (SEQ ID NO.17);
[0068] H12:CTTGTCACACAGAGCGAACAATGCACCATCAACAGGTGTCA (SEQ ID NO. 18);
[0069] H13: TGACACCTGTTGATGGTGCATTGTTCGCTCTGTGTGACAAG (SEQ ID NO. 19);
[0070] H14: TTAGTTTTCCAGTACTCGTG (SEQ ID NO. 20).
[0071] Example 3 Knockout of ygeA gene
[0072] The nucleotide sequence of the ygeA gene referred to in the present invention is shown in SEQ ID NO. 5. The ygeA sequence after gene knockout in this example is shown in SEQ ID NO. 6.
[0073] Using genetic mutations Site-Directed Mutagenesis kit, designed primers H15 and H16 to mutate pTargetF vector. The mutated N20 sequence was TCTGCCTTTCTTACACATTG (SEQ ID NO.28), targeting ygeA gene. The mutated pTargetF was named pTargetFyA.
[0074] Using the E. coli MG1655 genome as a template, primers H17 and H18 were used to amplify the upstream sequence of the ygeA gene using Norwegian PhantaFlash high-fidelity DNA polymerase, and primers H19 and P20 were used to amplify the downstream sequence of ygeA. The upstream and downstream fragments were recovered by gel excision and these two fragments were used as templates. The gene editing template DonoryA for knocking out ygeA was obtained by overlapping PCR using primers H17 and H20 at both ends.
[0075] The E. coli MG1655△thrB / pCas strain was selected and placed in a 500 mL shake flask containing 50 mL of LB containing kanamycin and cultured at 30°C and 220 rpm. 600 When the OD was 0.2, arabinose with a final concentration of 10 mM was added for induction. 600 Prepare competent cells when the p-value is 0.4. Take 2 microliters of pTargetFyA plasmid and 10 microliters of DonoryA template DNA, electrotransform into MG655 / pCas9 competent cells, spread on double-resistant plates containing 50 mg / L kanamycin and 50 mg / L spectinomycin, and culture at 30°C. Use primers P17 and P20 to identify single colonies with bases knocked out from -7 to 431 of the ygeA gene. Select the single colonies with the correct sequencing, add 0.2mM IPTG for culture, eliminate the pTargetFtB plasmid, and obtain the engineered bacteria E.coliMG1655△thrBygeA / pCas. Further inoculate into non-resistant LB liquid culture medium, culture at 37°C for 12h, dilute and spread on LB plates, and obtain the engineered bacteria E.coliMG1655△thrBygeA that eliminates the pCas plasmid.
[0076] H15:TTACACATTGGTTTTAGAGCTAGAAATAGC (SEQ ID NO. 21);
[0077] H16: GAAAGGCAGAGACTAGTATTATACCTAGG (SEQ ID NO. 22);
[0078] H17: GTCACGCTGGAACATATCGA (SEQ ID NO. 23);
[0079] H18: GCTTCAGGAATAAGACAATTGTCCTGATGTGTGTTACCG (SEQ ID NO. 24);
[0080] H19: CGGTAACACACATCAGGACAATTGTCTTATTCCTGAAGC (SEQ ID NO. 25);
[0081] H20: CAGTAAACCAATTTCTGTGCAG (SEQ ID NO. 26).
[0082] The vector pACYC184-thrA-ppc-asd constructed in Example 1 was transformed into the above-mentioned engineered bacteria E. coli MG1655△thrB and E. coli MG1655△thrBygeA to obtain engineered bacteria E. coli MG1655△thrB / pACYC184-thrA-ppc-asd and E. coli MG1655△thrBygeA / pACYC184-thrA-ppc-asd, respectively, for fermentation production of L-homoserine.
[0083] Example 4 Shake flask fermentation test of L-homoserine engineering bacteria
[0084] Take out the strain from the -80℃ refrigerator and streak it on the LB (or add corresponding antibiotics) plate, place it in a 37℃ constant temperature incubator, and culture it overnight. Pick the colonies on the plate to the slant culture medium, and quickly and densely streak from the bottom of the slant test tube to the mouth of the test tube. After plugging the cotton plug, place it in a 37℃ constant temperature incubator for 12 hours. Use a large inoculation loop to scrape a full ring of bacteria from the bottom of the slant to the mouth of the test tube, transfer it to the LB liquid culture medium, place it in a 37℃ shaker, 220rpm, and culture it for 12 hours. Take the seed liquid and transfer it to a 500mL baffled shake flask containing 30mL shake flask fermentation medium at a ratio of 3%, place it in a 37℃ shaker, and culture it continuously for 24 hours at 220rpm. Take samples every 4 hours, and adjust the pH value of the fermentation liquid with ammonia water to maintain it at 6.8-7.0. Dilute a portion of the sample taken out with 25% hydrochloric acid at different times and measure its OD 600 The other part was placed in a centrifuge and centrifuged at 12000×g for 2 minutes. The precipitate was discarded and the supernatant was saved for later use. The supernatant sample prepared by sampling was diluted 50 times and the residual sugar concentration was detected using a biosensor analyzer SBA-40D. When the residual sugar was lower than 5g / L, 10g / L glucose and 0.1g / L threonine were added.
[0085] Culture medium formula: glucose 20.0g / L, ammonium sulfate 15.0g / L, potassium dihydrogen phosphate 2.0g / L, magnesium sulfate heptahydrate 2.0g / L, yeast powder 2.0g / L, corn steep liquor 2.0g / L, isoleucine 0.6g / L, threonine 1.5g / L, calcium carbonate 15.0g / L, FeSO 4. 7H2O0.05g / L and MnSO 4. 4H2O0.05g / L.
[0086] After 24h of shake flask fermentation, the production of L-homoserine was detected, and the production of L-homoserine amino acid was detected by HPLC. Mobile phase A: pure acetonitrile. Mobile phase B: 50mM sodium acetate buffer, pure water, acetonitrile, triethylamine (82.8:17:0.2) acetic acid to adjust pH to 4.9. Derivatization reagent I: 0.2700gCNBF (3,5-dinitro-4-chloro-trifluoromethylbenzene) / 10ml acetonitrile; buffer II: pH9.0H3BO3-Na2B4O7 buffer: 0.2mol / L boric acid and 0.05mol / L borax solution. After preparation, it needs to be stored away from light. Derivatization method: dilute the sample to 0.1-2g / L, 100μL sample, 300μL derivatization reagent I, 500μL buffer II. Place in a mixer, 60℃, 400rpm, away from light for 1h. After the reaction is completed, the solution is filtered through a 0.22 μm syringe organic filter membrane and kept for detection. Detection conditions: chromatographic column: J&KC18-H Column (4.6×250 mm, 5 μm); flow rate: 0.80 mL / min; column temperature: 30°C; injection volume: 10.0 μL; detection wavelength: 260 nm.
[0087] After the fermentation was completed, the results of the L-homoserine production test were shown in Table 3. The results showed that after the ygeA gene was knocked out, the fermentation yield of L-homoserine was significantly increased.
[0088] Table 3
[0089]
[0090] SEQ ID NO.1:
[0091] GGA
[0092] SEQ ID NO.2:
[0093] atgAACGAACAATATTCCGCATTGCGTAGTAATGTCAGTATGCTCGGCAAAGTGCTGGGAGAAACCATCAAGGATGCGTTGGGAGAACACATTCTTGAACGCGTAGAAACTATCCGTAAGTTGTCGAAATCTTCACGCGCTGGCAATGATGCTAACCGCCAGGAGTTGCTCACCACCTTACAAAATTTGTCGAACGACGAGCTGCTGCCCGTTGCGCGTGCGTTTAGTCAGTTCCTGAACCTGGCCAACACCGCCGAGCAATACCACAGCATTTCGCCGAAAGGCGAAGCTGCCAGCAACCCGGAAGTGATCGCCCGCACCCTGCGTAAACTGAAAAACCAGCCGGAACTGAGCGAAGACACCATCAAAAAAGCAGTGGAATCGCTGTCGCTGGAACTGGTCCTCACGGCTCACCCAACCGAAATTACCCGTCGTACACTGATCCACAAAATGGTGGAAGTGAACGCCTGTTTAAAACAGCTCGATAACAAAGATATCGCTGACTACGAACACAACCAGCTGATGCG
[0094] TCGCCTGCGCCAGTTGATCGCCCAGTCATGGCATACCGATGAAATCCGTAAGCTGCGTCC
[0095] AAGCCCGGTAGATGAAGCCAAATGGGGCTTTGCCGTAGTGGAAAACAGCCTGTGGCAA
[0096] GGCGTACCAAATTACCTGCGCGAACTGAACGAACAACTGGAAGAGAACCTCGGCTACA
[0097] AACTGCCCGTCGAATTTGTTCCGGTCCGTTTTACTTCGTGGATGGGCGGCGACCGCGAC
[0098] GGCAACCCGAACGTCACTGCCGATATCACCCGCCACGTCCTGCTACTCAGCCGCTGGAA
[0099] AGCCACCGATTTGTTCCTGAAAGATATTCAGGTGCTGGTTTCTGAACTGTCGATGGTTGA
[0100] AGCGACCCCTGAACTGCTGGCGCTGGTTGGCGAAGAAGGTGCCGCAGAACCGTATCGC
[0101] TATCTGATGAAAAACCTGCGTTCTCGCCTGATGGCGACACAGGCATGGCTGGAAGCGCG
[0102] CCTGAAAGGCGAAGAACTGCCAAAACCAGAAGGCCTGCTGACACAAAACGAAGAACT
[0103] GTGGGAACCGCTCTACGCTTGCTACCAGTCACTTCAGGCGTGTGGCATGGGTATTATCGC
[0104] CAACGGCGATCTGCTCGACACCCTGCGCCGCGTGAAATGTTTCGGCGTACCGCTGGTCC
[0105] GTATTGATATCCGTCAGGAGAGCACGCGTCATACCGAAGCGCTGGGCGAGCTGACCCGC
[0106] TACCTCGGTATCGGCGACTACGAAAGCTGGTCAGAGGCCGACAAACAGGCGTTCCTGAT
[0107] CCGCGAACTGAACTCCAAACGTCCGCTTCTGCCGCGCAACTGGCAACCAAGCGCCGAA
[0108] ACGCGCGAAGTGCTCGATACCTGCCAGGTGATTGCCGAAGCACCGCAAGGCTCCATTGC
[0109] CGCCTACGTGATCTCGATGGCGAAAACGCCGTCCGACGTACTGGCTGTCCACCTGCTGC
[0110] TGAAAGAAGCGGGTATCGGGTTTGCGATGCCGGTTGCTCCGCTGTTTGAAACCCTCGAT
[0111] GATCTGAACAACGCCAACGATGTCATGACCCAGCTGCTCAATATTGACTGGTATCGTGGC
[0112] CTGATTCAGGGCAAACAGATGGTGATGATTGGCTATTCCGACTCAGCAAAAGATGCGGG
[0113] AGTGATGGCAGCTTCCTGGGCGCAATATCAGGCACAGGATGCATTAATCAAAACCTGCG
[0114] AAAAAGCGGGTATTGAGCTGACGTTGTTCCACGGTCGCGGCGGTTCCATTGGTCGCGGC
[0115] GGCGCACCTGCTCATGCGGCGCTGCTGTCACAACCGCCAGGAAGCCTGAAAGGCGGCC
[0116] TGCGCGTAACCGAACAGGGCGAGATGATCCGCTTTAAATATGGTCTGCCAGAAATCACC
[0117] GTCAGCAGCCTGTCGCTTTATACCGGGGCGATTCTGGAAGCCAACCTGCTGCCACCGCC
[0118] GGAGCCGAAAGAGAGCTGGCGTCGCATTATGGATGAACTGTCAGTCATCTCCTGCGATG
[0119] TCTACCGCGGCTACGTACGTGAAAACAAAGATTTTGTGCCTTACTTCCGCTCCGCTACGC
[0120] CGGAACAAGAACTGGGCAAACTGCCGTTGGGTTCACGTCCGGCGAAACGTCGCCCAAC
[0121] CGGCGGCGTCGAGTCACTACGCGCCATTCCGTGGATCTTCGCCTGGACGCAAAACCGTC
[0122] TGATGCTCCCCGCCTGGCTGGGTGCAGGTACGGCGCTGCAAAAAGTGGTCGAAGACGG
[0123] CAAACAGAGCGAGCTGGAGGCTATGTGCCGCGATTGGCCATTCTTCTCGACGCGTCTCG
[0124] GCATGCTGGAGATGGTCTTCGCCAAAGCAGACCTGTGGCTGGCGGAATACTATGACCAA
[0125] CGCCTGGTAGACAAAGCACTGTGGCCGTTAGGTAAAGAGTTACGCAACCTGCAAGAAG
[0126] AAGACATCAAAGTGGTGCTGGCGATTGCCAACGATTCCCATCTGATGGCCGATCTGCCG
[0127] TGGATTGCAGAGTCTATTCAGCTACGGAATATTTACACCGACCCGCTGAACGTATTGCAG
[0128] GCCGAGTTGCTGCACCGCTCCCGCCAGGCAGAAAAAGAAGGCCAGGAACCGGATCCTC
[0129] GCGTCGAACAAGCGTTAATGGTCACTATTGCCGGGATTGCGGCAGGTATGCGTAATACCGGCtaa。
[0130] SEQ ID NO.3:
[0131]
[0132] SEQ ID NO.4
[0133] atgGTTAAAGTTTATGCCCCGGCTTCCAGTGCCAATATGAGCGTCGGGTTTGATGTGCTCGGGGCGGCGGTGACACCTGTTGATGGTGCATTGCTCGGAGATGTAGTCACGGTTGAGGCGGCAGAGACATTCAGTCTCAACAACCTCGGACGCTTTGCCGATAAGCTGCCGTCAGAACCACGGGAAAATATCGTTTATCAGTGCTGGGAGCGTTTTTGCCAGGAACTGGGTAAGCAAATTCCAGTGGCGATGACCCTGGAAAAGAATATGCCGATCGGTTCGGGCTTAGGCTCCAGTGCCTGTTCGGTGGTCGCGGCGCTGATGGCGATGAATGAACACTGCGGCAAGCCGCTTAATGACACTCGTTTGCTGGCTTTGATGGGCGAGCTGGAAGGCCGTATCTCCGGCAGCATTCATTACGACAACGTGGCACCGTGTTTTCTCGGTGGTATGCAGTTGATGATCGAAGAAAACGACATCATCAGCCAGCAAGTGCCAGGGTTTGATGAGTGGCTGTGGGTGCTGGCGTATCCGGGGATTAAAGTCTCGACGGCAGAAGCCAGGGCTATTTTACCGGCGCAGTATCGCCGCCAGGATTGCATTGCGCACGGGCGACATCTGGCAGGCTTCATTCACGCCTGCTATTCCCGTCAGCCTGAGCTTGCCGCGAAGCTGATGAAAGATGTTATCGCTGAACCCTACCGTGAACGGTTACTGCCAGGCTTCCGGCAGGCGCGGCAGGCGGTCGCGGAAATCGGCGCGGTAGCGAGCGGTATCTCCGGCTCCGGCCCGACCTTGTTCGCTCTGTGTGACAAGCCGGAAACCGCCCAGCGCGTTGCCGACTGGTTGGGTAAGAACTACCTGCAAAATCAGGAAGGTTTTGTTCATATTTGCCGGCTGGATACGGCGGGCGCACGAGTACTGGAAAACtaa。
[0134] SEQ ID NO.5:
[0135] atgAAAACAATTGGTTTGCTGGGAGGAATGAGCTGGGAATCCACCATTCCTTACTATCGTTTGATAAATGAAGGCATTAAACAGCGGCTTGGTGGGCTTCACTCTGCGCAAGTGCTGCTACATAGCGTCGATTTTCATGAAATAGAAGAGTGCCAGCGTCGCGGGGAATGGGATAAAACCGGGGACATTCTGGCTGAGGCGGCGCTTGGCTTACAGCGGGCGGGCGCAGAAGGTATTGTGCTATGTACCAATACGATGCATAAAGTGGCGGATGCCATTGAGTCACGTTGCACTCTGCCTTTCTTACACATTGCGGATGCCACCGGACGTGCAATTACCGGGGCCGGAATGACTCGTGTGGCGCTGCTGGGTACGCGTTACACCATGGAACAGGATTTTTATCGCGGGCGGCTGACGGAACAATTTTCCATCAATTGTCTTATTCCTGAAGCGGATGAACGGGCGAAAATTAATCAGATTATTTTTGAAGAACTGTGTCTGGGGCAATTTACCGAAGCGTCACGCGCTTATTGTGCGCAAGTGATTGCTCGCCTTGCAGAACAGGGCGCACAGGGCGTCATTTTTGGCTGCACAGAAATTGGTTTACTGGTGCCAGAAGAGCGCAGTGTTTTGCCTGTGTTTGATACCGCGGCGATCCATGCCGAGGATGCTGTCGCTTTTATGCTGTCGtag。
[0136] SEQ ID NO.6:
[0137] GTCACGCTGGAACATATCGAACGCAAACTGATGGCAGGCGAGAAGTTGAGAAATATCGGCGTCTGATTTCACGGGCCGGATGTGCTGTACATCCGGCCCTTTTTCGTTAATAGAGATTGGGCACTTGGCCGTTGAGGCGTTTGTCTCGTTCCTTATTCAGCCTTGTTGCGGTAACACACATC AGGACAATTGTCTTATTCCTGAAGCGGATGAACGGGCGAAAATTAATCAGATTATTTTTGAAGAACTGTGTCTGGGGCAATTTACCGAAGCGTCACGCGCTTATTGTGCGCAAGTGATTGCTCGCCTTGCAGAACAGGGCGCACAGGGCGTCATTTTTGGCTGCACAGAAATTGGTTTACTG.
[0138] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. An engineered bacterium for producing L-homoserine by fermentation, characterized in that: The initial strain of the engineered bacteria is Escherichia coli, and only by completely or partially knocking out the Escherichia coli ygA Genes and tB Gene, overexpression thrA Mutated genes, ppc Genes and asd The gene expression vector is constructed to obtain the engineering bacteria; Said ygA The nucleotide sequence of the gene is shown in SEQ ID NO.5; Said tB The nucleotide sequence of the gene is shown in SEQ ID NO.4; Said thrA The nucleotide sequence of the mutant gene is obtained by mutating the bases at 1297-1299 bp of the nucleotide sequence shown in SEQ ID NO.1 to bases encoding arginine; Said ppc The nucleotide sequence of the gene is shown in SEQ ID NO.2; Said asd The nucleotide sequence of the gene is shown in SEQ ID NO.
3.
2. The engineered bacteria according to claim 1, characterized in that The Escherichia coli is Escherichia coli K12 MG1655.
3. A method for constructing an engineered bacterium for producing L-homoserine by fermentation as claimed in claim 1, characterized in that: The following steps are involved: Escherichia coli tB The gene was completely or partially knocked out to obtain tB Loss of gene function E. coli MG1655△ tB ; The E. coli MG1655△ tB of ygA The gene was completely or partially knocked out to obtain tB Genes and ygA Loss of gene function E. coli MG1655△ thrBygeA ; In the E. coli MG1655△ thrBygeA Overexpression thrA Mutated genes, ppc Genes and asd Gene expression vector to obtain the engineered bacteria; Said thrA The nucleotide sequence of the mutant gene is obtained by mutating the bases at 1297-1299 bp of the nucleotide sequence shown in SEQ ID NO.1 to bases encoding arginine; Said ppc The nucleotide sequence of the gene is shown in SEQ ID NO.2; Said asd The nucleotide sequence of the gene is shown in SEQ ID NO.3; Said tB The nucleotide sequence of the gene is shown in SEQ ID NO.4; Said ygA The nucleotide sequence of the gene is shown in SEQ ID NO.
5.
4. The construction method according to claim 3, characterized in that: Using CRISPR / Cas9 method tB Genes and ygA Knock out a gene in whole or in part.
5. The construction method according to claim 3, characterized in that: The Escherichia coli is Escherichia coli K12MG1655.
6. Use of the engineered bacteria according to any one of claims 1 to 2 in the fermentation production of L-homoserine.
7. A method for producing L-homoserine by fermentation, characterized in that: The method comprises the step of producing L-homoserine by fermentation using the engineered bacteria described in any one of claims 1 to 2.
Citation Information
Patent Citations
L-homoserine producing strain, and construction method and application thereof
CN108504613A
Production strain of L-homoserine, construction method and application of production strain
CN112725254A
Genetically engineered bacterium for producing L-homoserine and application of genetically engineered bacterium
CN112779204A
Recombinant escherichia coli for producing L-homoserine and application thereof
CN115109738A
